End points were measured from baseline to week 52. Values are derived from an analysis of variance for the treatment policy estimand (top part of table) and a mixed-model-for-repeated-measures ...
Demonstrated a favorable safety and tolerability profile for VG-3927 across all cohorts, including elderly participants, with no serious adverse events reported. Achieved robust and dose-dependent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback